|
|
Post by radgray68 on Jun 20, 2023 20:22:01 GMT -5
Deplorable? Unlocking shareholder value? Have you listened to the updates we've gotten in the last month? Try the RBC capital markets one again. It'll knock your socks off.
In 6 years we've gone from a financial death spiral to solid foundation. A $10,000 investment would have returned $57,000 today. That's over 470% ROI and 33% annualized.
If that's deplorable then sign me up again and again. To quote a line from the princess bride, "You keep using that word. I do not think it means what you think it means."
|
|
|
|
Post by markado on Jun 20, 2023 20:50:24 GMT -5
Deplorable? Unlocking shareholder value? Have you listened to the updates we've gotten in the last month? Try the RBC capital markets one again. It'll knock your socks off. In 6 years we've gone from a financial death spiral to solid foundation. A $10,000 investment would have returned $57,000 today. That's over 470% ROI and 33% annualized. If that's deplorable then sign me up again and again. To quote a line from the princess bride, "You keep using that word. I do not think it means what you think it means." No, that was "inconceivable," but I will admit it is inconceivable that we sit at $4 per share while the market rallies around us, yet again. So, maybe "deplorable" is too strong a sentiment, how about "utterly disappointing is not phenomenal." For the record, I am sitting on a paper profit for my shares, and I bought a bunch at $1.05 many years ago. That doesn't mean I have to be satisfied with the current state. And, I don't think $4 per share has adequately unlocked shareholder value for many of the retail longs on this board, especially anyone who invested big before 2015. |
|
|
|
Post by prcgorman2 on Jun 20, 2023 21:49:05 GMT -5
Deplorable? Unlocking shareholder value? Have you listened to the updates we've gotten in the last month? Try the RBC capital markets one again. It'll knock your socks off. In 6 years we've gone from a financial death spiral to solid foundation. A $10,000 investment would have returned $57,000 today. That's over 470% ROI and 33% annualized. If that's deplorable then sign me up again and again. To quote a line from the princess bride, "You keep using that word. I do not think it means what you think it means." No, that was "inconceivable," but I will admit it is inconceivable that we sit at $4 per share while the market rallies around us, yet again. So, maybe "deplorable" is too strong a sentiment, how about "utterly disappointing is not phenomenal." For the record, I am sitting on a paper profit for my shares, and I bought a bunch at $1.05 many years ago. That doesn't mean I have to be satisfied with the current state. And, I don't think $4 per share has adequately unlocked shareholder value for many of the retail longs on this board, especially anyone who invested big before 2015. Warning: Long response... markado - I want to tell you I have sympathy for your patience having been worn. Success has been a long time coming. I invested in 2013, over-invested in 2014, dollar cost averaged for a long time. I too want to be in a better place. Where I’m at after all that is, “not horrible”. That’s not good enough. But, I’m more hopeful than I’ve ever been in 8 years. And, I’m relieved that it’s not 100% tied to Afrezza. Afrezza is a unicorn that I continue to hope isn’t the mirage that recedes relentlessly into a future never to be realized. The Cipla results should not hurt sales. The trial we’re hanging our hat on for Afrezza is the pediatric trial and it’s hard to wait for results next year. Tyvaso DPI isn’t the end all be all either. I (and Wall Street) want to see more. V-Go is OK, until it’s not, and consensus on our Proboard is V-Go isn’t likely to be missed much. But there seems to be some interest and enthusiasm in Clofazamine from posters I respect. I’ve not seen anything overtly positive or negative (that I remember) about Nintenadib. MC has emphasized these are the 2 most near-term candidates in the pipeline. Clofazamine is classified an “orphan drug” and has special consideration with the FDA. stevil shared that were Clofazamine proven to be effective against Non-Tuberculosis Mycobacteria, it might be very valuable. My view is MannKind wooed United Thereapeutics regarding Tyvaso DPI by showing interesting Phase 1 test results with Treprostinil on TechnoSphere. UTHR engaged 3 different (potential) competitors on Tyvaso. One they bought. One they sued. The other they partnered with; MannKind. I don’t expect UTHR is the only pharma paying attention to MannKind’s Phase 1 pipeline candidates. Mike is well-connected within the industry and will have gained substantial respect for what he’s accomplished both before MannKind and since he took the helm. I still sympathize with you. I hate the interminable waiting. But, as I said before, I’m more hopeful than ever. Good luck to you and all longs. |
|
|
|
Post by BD on Jun 20, 2023 23:04:15 GMT -5
SHV - my attempt to abbreviate shareholder value... As always diamond hands and GLTAL's! The "unlock" made it kind of obvious, at least to me... |
|
|
|
Post by hellodolly on Jun 21, 2023 6:46:12 GMT -5
The topic of this thread is the exact reason I stopped working as head of marketing for public companies about half way through my career. Shareholders have put too much emphasis on short term expectations (particularly tied to stock price) that don’t always align with the market place realities, or the company’s for that matter. Wasn’t it just a week or so ago that Mike had the governor of the state of Connecticut at MNKD’s facility announcing a massive increase in manufacturing capacity to meet the T-DPI demand? What was the impact on SHV? As a long time shareholder, I want Mike focused on delivering product that will deliver sustained revenue growth, not pumping the PR machine. PR for PR sake does not create sustainable shareholder value (buy the rumor, sell on the news?). I continue to be focused one to two years out when it comes to my investment in MNKD. The PR will come when there is something to blow the horn about, then it had better be really loud. Until then I will pass on the thousand press releases about little progress items, cause when the time comes to be loud, people will just shrug it off as simply another announcement from MNKD. As a shareholder 8 years running, with over 50k shares, I'm not concerned with every short term news bit. I am concerned that we go dark all too often. We over promise and under deliver equally as often. Mike simply doesn't present as being in control of the company's narrative, which is interpreted by the market as the company's direction. If he wants credit for executing on a vision, then he needs to share that vision ahead of delivery (the what, why and when) and then deliver on it. The recent mention of the delivery of Cipla data in a week or so, with a failure to deliver on it makes him look at best under-informed, at worst out of synch with their on the ground realities. Same for the Blue-Hale launch. At $4 a share you're damn right I'm a frustrated long, and no, I really don't want to wait another two years just hoping it will all work out. I sense you're very frustrated and have been for some time now based on your ongoing criticisms. Mike's comments regarding the India data being delivered is not and should not be interpreted as to mean "for public dissemination". It was quite clear that MNKD was going to get the data. I didn't hear Mike give a date as to when they would publicly release it, after their internal reviews. There had been some discussion on ProBoards that it was possibly being intentionally withheld as it would be an excellent opportunity to release it during the ADA Conference later this month. Who knows, maybe that's in the cards but in no way did I find his comment to be a commitment towards releasing the data so soon. What did the data tell them? How will they use it? Are they making plans in India? Answering those questions, before a public announcement needs to be considered before "willy-nilly" tossing it out to the public just for the sake of creating a sound bite or a "news drop". All that does is lead to more uncertainty and more questions. Everything is planned and calculated, especially the news they control, to derive the best possible outcome. MNKD shareholders were fortunate in 2022 that their SP actually beat the S&P returns. I didn't hear a word from unhappy investors in 2022. Did they have more "news drops". Not likely but, the build on Tyvaso likely had much to do with the performance. The market can't ignore MNKD forever. I'm intrigued when I read posts regarding investors here who have held MNKD shares for more than a decade but, won't hold longer. Silly perhaps, to me that after all this time...they would have made that decision five years ago. People with "diamond hands" don't ever let go, right? Maybe that was all really BS and a facade or it's simply now passe'? Just my thoughts on long term investing. I've discovered that some investors cope with the performance of their investment by setting their expectations and executing. They seem to be the a happiest and most satisfied investors because they executed the plan, which takes out the emotions..."Plan the trade, Trade the plan." Maybe switch tactics and sell while they have profits and get back in on the dips, or...is FOMO that bad they stick around for over a decade, become irrational, blame others for not making money and point fingers at management? Yes, your frustration is loud and clear. |
|
|
|
Post by sportsrancho on Jun 21, 2023 6:48:56 GMT -5
Disagree on the DTC ADD .. add wasn’t effective on its own merit…we’re an FDA approved drug with subjective convenience not seen before in diabetes… a DEXCOM STYLE ADD WOULD HAVE MADE ALL THE DIFFERENCE IN THE WORLD ..and still will .. watch the Dexcom add and insert Afrezza . I agree with this, because even the other commercial was just starting to gain traction, I’m sitting in an eye appointment, and the lady next to me, starts talking to another person about seeing this commercial about inhaled insulin. On another note….How many people here are on Instagram? Mannkind does a lot on there, talking about the activities of the company, and the organizations they are a part of, testimonials about working at the company ..and for Afrezza. I do agree about the press releases, they need to be more consistent. |
|
|
|
Post by prcgorman2 on Jun 21, 2023 8:11:35 GMT -5
I used to agree with more press releases and especially with DTC. The thing about Direct To Consumer advertising is you’re investing in awareness (which is good) but the call to action is the hard part. Afrezza can be sold to consumers only after it’s sold to prescribers (and insurers). Otherwise it’s a serious waste of capital. The prescribers are not beneficially influenced by commercials. If they were, I’d lose respect for them.
Selling CGMs is NOT the same as selling insulin. The worst that can happen with a CGM is it gives a bad (flawed) reading and the person with diabetes makes a bad decision on dosing themselves based on flawed information. That’s the reason for the prescriptions I believe. It’s to ensure the person with diabetes is informed and educated about their use and calibration to avoid the problems of organ damage, self-induced comas and death with under dosing or worse, over dosing with insulin. The risk with CGM misuse is extremely low as compared to insulin. For sure you can’t easily kill yourself with one. Doctors and diabetics both are taught insulin is scary because it can, and occassionally does, kill you. Glib commercials won’t cut it.
Once you can convince doctors and insurers that “Afrezza is the SAFE choice”, you’ll be able to do flying hamburgers and “move the needle” and not before then.
|
|
|
|
Post by akemp3000 on Jun 21, 2023 8:14:47 GMT -5
On a side note, the title of this thread is really strange. Makes me want to skip over it but I don't want to miss anything. Just sayin.
|
|
|
|
Post by akemp3000 on Jun 21, 2023 8:20:22 GMT -5
I used to agree with more press releases and especially with DTC. The thing about Direct To Consumer advertising is you’re investing in awareness (which is good) but the call to action is the hard part. Afrezza can be sold to consumers only after it’s sold to prescribers (and insurers). Otherwise it’s a serious waste of capital. The prescribers are not beneficially influenced by commercials. If they were, I’d lose respect for them. Selling CGMs is NOT the same as selling insulin. The worst that can happen with a CGM is it gives a bad (flawed) reading and the person with diabetes makes a bad decision on dosing themselves based on flawed information. That’s the reason for the prescriptions I believe. It’s to ensure the person with diabetes is informed and educated about their use and calibration to avoid the problems of organ damage, self-induced comas and death with under dosing or worse, over dosing with insulin. The risk with CGM misuse is extremely low as compared to insulin. For sure you can’t easily kill yourself with one. Doctors and diabetics both are taught insulin is scary because it can, and occassionally does, kill you. Glib commercials won’t cut it. Once you can convince doctors and insurers that “Afrezza is the SAFE choice”, you’ll be able to do flying hamburgers and “move the needle” and not before then. Pediatric approval is the golden ticket that will finally send the message to endos and pcps that the Afrezza method of human insulin delivery is very safe...and convenient, and easy to use, and eliminates or reduces meal-time spikes, and doesn't require a pump, and improves quality of life! |
|
|
|
Post by rickf on Jun 21, 2023 9:17:34 GMT -5
Deplorable? Unlocking shareholder value? Have you listened to the updates we've gotten in the last month? Try the RBC capital markets one again. It'll knock your socks off. In 6 years we've gone from a financial death spiral to solid foundation. A $10,000 investment would have returned $57,000 today. That's over 470% ROI and 33% annualized. If that's deplorable then sign me up again and again. To quote a line from the princess bride, "You keep using that word. I do not think it means what you think it means." No, that was "inconceivable," but I will admit it is inconceivable that we sit at $4 per share while the market rallies around us, yet again. So, maybe "deplorable" is too strong a sentiment, how about "utterly disappointing is not phenomenal." For the record, I am sitting on a paper profit for my shares, and I bought a bunch at $1.05 many years ago. That doesn't mean I have to be satisfied with the current state. And, I don't think $4 per share has adequately unlocked shareholder value for many of the retail longs on this board, especially anyone who invested big before 2015. You are 100% correct - I am down a LOT of money! I, along with many others here on this board, am down over $200K! So - yes - the sp needs to be significantly better and if I was not locked in to this equity I would have bailed a long time ago! My belief in a better "mouse trap" so far has backfired on me in a LARGE way! The folks I feel bad for though are the diabetics - this can be a gamer changer for a lot of them and the opportunity has ben , so far, squandered! |
|
|
|
Post by agedhippie on Jun 21, 2023 9:48:06 GMT -5
Pediatric approval is the golden ticket that will finally send the message to endos and pcps that the Afrezza method of human insulin delivery is very safe...and convenient, and easy to use, and eliminates or reduces meal-time spikes, and doesn't require a pump, and improves quality of life! I would be careful about expectations from the pediatrics trial. It's not going to change views, but what it will do is allow doctors to prescribe Afrezza for kids without going off-label. The numbers for adults have been available for years, pediatrics is treated as a different class (it's why there are separate adult and pediatric trials), so I don't see significant change in the adult market. If this is to change it's going to take trial data. Absent that we are trimming around the edges but not going anywhere. |
|
|
|
Post by wmdhunt on Jun 21, 2023 9:55:52 GMT -5
Why is this a $4 stock? I ask myself this day after day after day. Always seems we are on the "cusp" of something great but it never happens for us stockholders. If the future is so bright, then, why am I still watching this stock struggle for decades? I look at other startups and biomed companies that are less endowed with products, pipelines and prospects but their stock prices are higher. Fed up, that is what I am.
|
|
|
|
Post by cretin11 on Jun 21, 2023 10:07:02 GMT -5
Markado's observations are straightforward, measured and reasonable. Nobody can accuse markado of being a "short in disguise" like they try to accuse some posters who offer criticism. Interesting that the posts pushing back on markado tend to be convoluted and often employ strawman arguments to shift the narrative. It is upsetting to some whenever anyone suggests management could be doing more to unlock SHV. It's a fascinating pattern, the cognitive dissonance is powerful.
|
|
|
|
Post by prcgorman2 on Jun 21, 2023 10:17:02 GMT -5
When I was a kid, there were bumper stickers which read, "America, LOVE it or LEAVE it". Not sure if I ever agreed with the 2nd part of that, but it is understandable that some suggest that if something is making you miserable, change what YOU are doing because you can control yourself even if you can't control the management of an investment. MNKD is cheap which is both good and lamentable, but for sure, it's not a huge deal to sell now and jump back in if/when you feel like your investment will grow the way you want it to. Now if you're down big, my condolences if you were unwise with your money. My investment is substantial but I am not depending on this one investment for my future well-being. Nobody should. That is too many eggs in one basket. Another option for the miserable who complain, sell a portion of your investment and put it where you think it will do you more good. It will provide immediate emotional relief that some of you seem to need and I respect that.
|
|
|
|
Post by akemp3000 on Jun 21, 2023 10:17:18 GMT -5
Pediatric approval is the golden ticket that will finally send the message to endos and pcps that the Afrezza method of human insulin delivery is very safe...and convenient, and easy to use, and eliminates or reduces meal-time spikes, and doesn't require a pump, and improves quality of life! I would be careful about expectations from the pediatrics trial. It's not going to change views, but what it will do is allow doctors to prescribe Afrezza for kids without going off-label. The numbers for adults have been available for years, pediatrics is treated as a different class (it's why there are separate adult and pediatric trials), so I don't see significant change in the adult market. If this is to change it's going to take trial data. Absent that we are trimming around the edges but not going anywhere. I disagree wholeheartedly. As my pcp said to me, "We doctors have all been trained that prescribing insulin can only be the last resort because of safety. I would never prescribe insulin unless it's the last resort because of the possibility of hypos, emergency room or death". Once approved for pediatrics, the safety of prescribing human insulin with Afrezza will not only be huge news in the diabetes world but sales reps will be able to share this. It flips what doctors have been taught. Such news won't be confined to those only interested in pediatrics. IMO, this will be a huge game changer. So much so, it wouldn't be surprising to learn a BP is waiting on the approval to do a deal. I look forward to seeing what happens and my expectations are high. We'll see. |
|
